Please assess the completion status of the following clinical trial:

Trial Title: 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(1) They were pathologically diagnosed with DTC including papillary or follicular carcinoma. (2) They received a near total thyroidectomy and radioiodine treatment. (3) TSH suppression should be at least one year before the study. (4) Bone mineral density (BMD) in lumbar spine and/or hip was tested by Dual-energy X-ray absorptiometry (DXA) at baseline, 6 month (m) and/or 12m follow up. 5) The diagnosis of osteoporosis was T-score ≤-2.5 SD at the lumbar spine, or hip.~Exclusion Criteria:~1. patients having medications for osteoporosis before TSH suppression treatment;~2. secondary osteoporosis ;~3. severe liver or kidney disease;~4. myelosuppression;~5. digestive disease;~6. long term use of immunosuppressive agent, estrogen or estrogen receptor modulators. This study was approved by the Institutional Review Board of Hospital Research Ethics. All the patients were fully acquainted with their treatment and consented to participate in the clinical trial.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 99Tc-MDP (Type: EXPERIMENTAL): 15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
- Fosamax (Type: ACTIVE_COMPARATOR): 70mg po every week for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).